Psychedelics Investing Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap's Mental Health Technology
Psychedelics Investing Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange
Psychedelics Investing Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland
Psychedelics Investing Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
Psychedelics Investing Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia
Psychedelics Investing Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials
Psychedelics Investing Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials
Psychedelics Investing Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics
Psychedelics Investing Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms
